Immunicon Corp

Immunicon — Investor Presentation (November 2006)

26 slides from Immunicon's investor presentation, Nov 2, 2006

  1. Slide 1: Management Presentation November 2006

    Slide 1: Management Presentation November 2006

    Management Presentation November 2006 Cellular Information for Better Healthcare Circulating Tumor Cells Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain forward-looking statements that reflect management ’ s current views and opinions as to the status of the Company ’ s products, clinical trials, regulatory approval process, product development, research programs and other future events and op

  3. Slide 3: Immunicon Value Proposition

    Slide 3: Immunicon Value Proposition

    Immunicon Value Proposition Immunicon develops and commercializes proprietary cell- and molecular-based human diagnostic and life science research products Cancer products sold through Veridex, a Johnson & Johnson company – Received FDA clearances for our instruments and CellSearch™ Circulating Tumo

  4. Slide 4: CellTracks Products for Cellular Analysis

    Slide 4: CellTracks Products for Cellular Analysis

    CellTracks ® Products for Cellular Analysis Circulating Tumor Cell Kit Sample Collection and Preservation Standardized Rare Cell Capture Endothelial Cell Kit Sample Analysis Kits for Cell Counting

  5. Slide 5: CellTracks Products: CEC Kit, Profile Kit

    Slide 5: CellTracks Products: CEC Kit, Profile Kit

    CEC Kit Profile Kit CellTracks ® Products Marker Reagents for Characterization for Targeted Therapy * HER-2/neu * EGFr * IGF-1R * bcl-2 * M30 * other candidates with Pharma Enrichment Kits for Downstream Molecular Analysis FISH in cartridge (in development) Cancer Confirmation Gene Amplification Hea

  6. Slide 6: CTCs as a "Real-Time Biopsy"

    Slide 6: CTCs as a "Real-Time Biopsy"

    CTCs as a “ Real-Time Biopsy ” Blood Test Most tumors are of epithelial cell origin: Isolation of epithelial cells may mean pan - carcinoma capability Count Phenotype & Genotype Assess Prognosis Direct Therapy Monitor Disease Diagnose Specify Therapy Circulating Tumor Cells (CTCs) and Associated Mar

  7. Slide 7: Circulating Tumor Cells Predict Survival

    Slide 7: Circulating Tumor Cells Predict Survival

    Circulating Tumor Cells Predict Survival Time from Baseline (Months) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Logrank p < 0.0001 21.9 Months 10.9 Months > 5 CTCs n=87 (49%) <5 CTCs n=90 (51%) NEJM 2004, ASCO 2004 / 2005 Before initiation of therapy

  8. Slide 8: Change in CTCs Predict Survival

    Slide 8: Change in CTCs Predict Survival

    Change in CTCs Predict Survival Package Insert, October 2005 Clinical Cancer Research, July 2006 green vs. red p=0.0001 green vs. blue p=0.3188 green vs. orange p=0.0014 blue vs. red p=0.0002 22.6 mo. 19.8 mo. 10.6 mo. 4.1 mo. Time from Baseline (months) < 5 CTCs at First and Last Draw 83 (47%) >5 C

  9. Slide 9: Any CTCs Impact Survival: Treat to Zero!

    Slide 9: Any CTCs Impact Survival: Treat to Zero!

    Any CTCs Impact Survival: Treat to Zero! CTC / 7.5 ml blood Median 95% Low limit 95% Upper limit 29% 71% 61% 56% 51% 48% 45% 43% 43% 40% 36% =0 >1 >2 >3 >5 >7 >8 >9 >6 >4 >10 Median 95% Low limit 95% Upper limit =0 >1 >2 >3 >5 >7 >8 >9 >6 >4 >10 223 patients San Antonio Breast Cancer Symposium 2005

  10. Slide 10: A New Standard for Cancer Disease Management

    Slide 10: A New Standard for Cancer Disease Management

    A New Standard for Cancer Disease Management Future standard: Number, protein expression, and/or gene expression of CTCs better reflects efficacy of treatment Current standard: Radiologist measures changes in lesions on a CT scan to assess tumor burden increase/decrease Objective, quantitative 3-4 w

  11. Slide 11: CTC versus CT Scans to Predict Survival

    Slide 11: CTC versus CT Scans to Predict Survival

    CT Scans 11.9 +5.7 weeks *Centralized Review by Two Independent Radiologist. Third Radiologist was used in cases of disagreement (11%) CTC versus CT Scans to Predict Survival CCR in press / ASCO 2005 23.8 Months 6.4 Months S/PR & <5CTCs n=84 (61%) PD & <5CTCs n=20 (14%) S/PR & >5CTCs n=12 (9%) PD &

  12. Slide 12: Personalized Medicine: Her2 and targeted therapy selection

    Slide 12: Personalized Medicine: Her2 and targeted therapy selection

    Her2 - Her2 + Her2 ++ Her2 +++ Time (weeks) Taxol Herceptin Int J Oncol 21: 1111-1118, 2002 “Personalized Medicine” Enables selection of targeted therapies

  13. Slide 13: Cancer Confirmatory Test

    Slide 13: Cancer Confirmatory Test

    Leukocyte Tumor Cell Cancer Confirmatory Test Chromosome 1 Chromosome 7 Chromosome 8 2 x1, 2 x 7, 2 x 8 3 x1, 5 x 7, 4 x 8

  14. Slide 14: Assessment of Treatment Targets on CTCs

    Slide 14: Assessment of Treatment Targets on CTCs

    PNAS , 101: 9393-9398, Cytokeratin Her-2 Her-2 protein CEP 17 Her-2 gene CEP 17 / Her-2 gene 1+: 1.0 3+: 3.5 2+: 1.7 Assessment of Treatment Targets on CTCs

  15. Slide 15: Significant Clinical Utility of Circulating Tumor Cells

    Slide 15: Significant Clinical Utility of Circulating Tumor Cells

    Significant Clinical Utility of Circulating Tumor Cells Patient Management Early evidence of treatment failure: gives the oncologist information to change therapy within weeks Predictive at any time point during treatment CTCs predict survival time in patients undergoing chemo & hormonal therapy CTC

  16. Slide 16: Advanced Technology for Simple Cell Counting

    Slide 16: Advanced Technology for Simple Cell Counting

    Instrument Rapid, accurate automated counts Simple to use 2-color analysis Uses proven technology Kits Simple cell counting (ViaSure) Immunomagnetic - Selection (IMS) Isolate and count specific cells Advanced Technology for Simple Cell Counting

  17. Slide 17: Research and Clinical Development Programs

    Slide 17: Research and Clinical Development Programs

    Research and Clinical Development Programs Colorectal cancer – endpoints achieved! Prostate cancer: 2Q07 FDA submission on 200 patient study Research studies – CTCs in early stage breast cancer and colorectal cancer – Impact on survival of changing therapy based on CTCs (SWOG) Develop FISH technolog

  18. Slide 18: Success in Pivotal Clinical Trial in Metastatic Colorectal Cancer

    Slide 18: Success in Pivotal Clinical Trial in Metastatic Colorectal Cancer

    Success in Pivotal Clinical Trial in Metastatic Colorectal Cancer Primary and secondary endpoints were achieved – Primary – agreement with imaging – Secondary - predict progression-free survival and overall survival. Large, multi-center trial – 481 patients; 55 sites in US and Europe Anticipate late

  19. Slide 19: Product Commercialization

    Slide 19: Product Commercialization

    Product Commercialization Oncologists Pathologists/laboratories Pharma Services Molecular Diagnostics Products and Services Life Science Research Instruments and Kits Infectious Disease Diagnostics

  20. Slide 20: Summary of instrument shipments and sales

    Slide 20: Summary of instrument shipments and sales

    Summary of instrument shipments and sales Year ended Six months end Three months end Cumulative @ June 30, 2006 Instrument shipments CellTracks Analyzer II CellSpotter (6) - Total Analyzers CellTracks AutoPreps Instruments sold (1) Total CellTracks Analyzer II Total CellSpotter - Total Analyzers Tot

  21. Slide 21: System Placements, by Customer/Geography

    Slide 21: System Placements, by Customer/Geography

    System Placements, by Customer/Geography Third party: 54.5 Total Placements: 75 CellTracks Analyzer II Upgrade 7.5 1.0 1.0 5.5 Veridex internal use Pharma/CRO Reference Lab 35.5 19.5 Hospital/Practice Total Shipments Total Japan/ Asia EU USA As of 9/30/06

  22. Slide 22: Financial Status

    Slide 22: Financial Status

    Financial Status Cash burn guidance for 2006 - $20 to $22 million Headcount at September 30, 2006 = 106 Borrowing capacity of $12.0 million @ =9/30/06 September 30, 2006 December 31, 2005 Cash and cash equivalents 29,535 $ 44,098 $ 9 months ended 9/30/06 9 months ended 9/30/05 Product & service reve

  23. Slide 23: Milestones Achieved

    Slide 23: Milestones Achieved

    Milestones Achieved Publications in major journals ( NEJM, CCR, JCO) U.S. in vitro diagnostic (IVD) launch 3Q04 510(k) clearance of expanded data Oct. 2005 Trial in colorectal cancer – endpoints met Sep. 2006 Trial in prostate cancer enrollment complete Jan. 2006 Kreatech license agreement for FISH

  24. Slide 24: Upcoming Milestones/Presentations

    Slide 24: Upcoming Milestones/Presentations

    Upcoming Milestones/Presentations Colorectal cancer 510(k)indication 1H07 Prostate cancer 510(k)indication 3Q07 Scientific meetings – CHI Clinical Trial Workshop Nov. 2006 – San Antonio Breast Cancer Symposium Dec. 2006 – Cell Biology Conference Dec. 2006 – Molecular Tri-Conference Workshop Feb. 200

  25. Slide 25: Immunicon Value Proposition

    Slide 25: Immunicon Value Proposition

    Immunicon Value Proposition Immunicon develops and commercializes proprietary cell- and molecular-based human diagnostic and life science research products Cancer products sold through Veridex, a Johnson & Johnson company – Received FDA clearances for our instruments and CellSearch™ Circulating Tumo

  26. Slide 26: Contact Information

    Slide 26: Contact Information

    Contact Information Masons Mill Road, Suite Huntingdon Valley, Pennsylvania phone 215.830.0777 fax 215.830.0751 web www.immunicon.com

Source: SEC EDGAR · 8-K filed Nov 2, 2006

More decks from Immunicon Corp